Fortier, Louis-Charles

Professeur, Faculté de médecine et des sciences de la santé
FMSS Dép. de microbiologie et infectiologie

Coordonnées

Courriel


819-821-8000, poste 75322


Site Web

Diplômes

(2007) Postdoctorat (Postdoctorat en sciences). Université Laval.

(2001) Doctorat (Doctorat en science des aliments). McGill University.

(1996) Maîtrise avec mémoire (Maîtrise ès Sciences - Maîtrise). Université de Sherbrooke.

(1994) Baccalauréat (Baccalauréat en Biologie). Université de Sherbrooke.

Expérience académique

(2019) President - Faculty's animal ethics review board. Université de Sherbrooke.

(2017) Professor (Full) / Professeur Titulaire. Université de Sherbrooke.

(2016) Assistant department head - research / Directeur adjoint à la recherche, département de microbiologie et d'infectiologie. Université de Sherbrooke.

(2012-2017) Associate professor / Professeur agrégé. Université de Sherbrooke.

(2011-2013) Director of graduate studies in microbiology / Directeur des programmes gradués en microbiologie. Université de Sherbrooke.

(2007-2012) Assistant professor / Professeur adjoint. Université de Sherbrooke.

(2004-2007) Postdoctoral fellow. Université Laval.

(2002-2004) Research professionnal. Université Laval.

Présentation

Sujets de recherche

Infections bactériennes, Virus (Organismes vivants), Micro-organismes, Mécanismes biologiques et biochimiques.

Disciplines de recherche

Microbiologie, Virologie.

Mots-clés

Clostridium difficile, Bactériophages, Microbiologie, Biologie moléculaire, Bioinformatique-génomique-transcriptomique, Expression génique, Sporulation, PCR en temps réel, Microscopie électronique, Expression de protéines.

Intérêts de recherche

Clostridium difficileJe m'intéresse aux infections à en général, incluant les aspects épidémiologiques, la pathogenèse des infections, la virulence et l'évolution de et le développement de nouveaux traitements contre les infections à . J'ai un intérêt particulier pour les bactériophages infectant et le rôle que ceux-ci jouent dans l'évolution de la bactérie et dans l'intestin. Je m'intéresse aussi aux phages infectant d'autres clostridies d'intérêt, comme , et les clostridies commensales. Je développe aussi des projets axés sur les analyses du microbiome et du virome intestinal.

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français

Prix et distinctions

  • (2017) Pharmacology prize / Prix de Pharmacologie (This prize was given by the students of Pharmacology to recognize the quality of my teaching). Université de Sherbrooke. (Prix / Récompense).
  • (2016) Junior 2 Salary Award. Fonds de recherche du Québec - Santé (FRQS). (Prix / Récompense).
  • (2012) Junior 1 Salary Award. Fonds de recherche du Québec - Santé (FRQS). (Prix / Récompense).
  • (2008) Salary award. I got this award from the CRCHUS based on my good ranking at the previous FRQS Junior 1 competition (I got my Junior 1 award on the second try). Centre de recherche clinique Étienne-Le Bel. (Prix / Récompense).
  • (2007) Postdoc scholarship. CRMUS. (Prix / Récompense).
  • (2000) PhD Scholarship. Fondation des Gouverneurs - Agriculture Canada (CRDA, St-Hyacinthe). (Prix / Récompense).
  • (1999) PhD scholarship. FCAR. (Prix / Récompense).
  • (1998) First prize-oral competition-biotechnology. Institute of Food Technology. (Prix / Récompense).
  • (1997) PhD Scholarship from the French Government. French Government. (Prix / Récompense).
  • (1996) M.Sc. Scholarship. Medical Research Council of Canada. (Prix / Récompense).
  • (1995) M.Sc. Scholarship. Faculty of medicine of the Université de Sherbrooke. (Prix / Récompense).

Financement

Subvention. (Obtenu). Co-demandeur. Epithelial-specific role of SOCS1 in prevention of intestinal inflammation. Instituts de Recherche en Santé du Canada (IRSC). Projet. 1030000 $ (2019-2024).

Subvention. (Obtenu). Chercheur principal. Phage biology and diversity in Clostridium difficile and other commensal clostridia. (2015-2020).

Subvention. (Obtenu). Co-demandeur. Replacement for Microbial Growth Assay Cluster. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Research Tools and Instruments. 143350 $ (2019-2020).

Subvention. (Obtenu). Co-demandeur. Impact de la concentration en métalloprotéinases 1-2-8-9, d’Enterococcus faecalis, de Pseudomonas aeruginosa et de Klebsiella sur le taux de fuite pancréatique post Whipple.. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Programme de financement interne. 25000 $ (2018-2019).

Subvention. (Obtenu). Chercheur principal. Mise en place et validation de la méthodologie pour l’analyse du virome. Centre de recherche du CHUS. Inflammation-Pain research axis. 16250 $ (2018-2019).

Subvention. (Obtenu). Chercheur principal. Isolation and characterization of Clostridium perfringens lytic phages for veterinary applications in the poultry industry. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Engage. 25000 $ (2018-2019).

Subvention. (Obtenu). Co-chercheur. Développement d'un modèle animal de déclenchement du travail par modification du microbiote intestinal pour une meilleure compréhension des facteurs impliqués dans la prématurité. Fondation des étoiles (La) (Qc). Fondation des étoles. 10000 $ (2017-2019).

Subvention. (Obtenu). Co-chercheur. Microbiote intestinal en grossesse et prématurité. Centre de recherche du CHUS. Programme d'Aide au Financement de la Recherche (PAFI). 25000 $ (2017-2019).

Subvention. (Obtenu). Co-demandeur. Replacement for Fast Protein Liquid Chromatography System. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Research Tools and Instruments. 138000 $ (2018-2019).

Subvention. (Obtenu). Co-demandeur. Rôle intrinsèque de SOCS1 dans l’épithélium intestinal et l'inflammation. Centre de recherche en inflammation et oncologie digestive de l’UdeS. operating grant. 15000 $ (2017-2018).

Subvention. (Obtenu). Co-chercheur. Prophylactic and therapeutic use of chenodeoxycholic acid (CDCA) against Clostridium difficile infection. Centre de recherche du CHUS. PAFI (internal funding program). 25000 $ (2016-2018).

Subvention. (Terminé). Chercheur principal. Gene expression control by riboswitches: mechanism and role in C. difficile biology and virulence - Modulation de l’expression génique par les riborégulateurs: mécanisme d’action et rôle dans la biologie et la virulence de C. difficile. (2014-2017).

Contrat. (Terminé). Chercheur principal. Therapeutic and prophylactic potential of egg yolk antibodies in the fight against Clostridium difficile infections. Immune Biosolutions inc. Collaborative research contract. 33574 $ (2015-2016).

Subvention. (Terminé). Chercheur principal. Anti-Clostridium difficile mechanisms of action of BioK+ probiotics - Étude des mécanismes d’action anti-Clostridium difficile par le probiotique Bio-K+. (2015).

Subvention. (Terminé). Chercheur principal. Phage biology and diversity in Clostridium difficile. (2010-2015).

Subvention. (Terminé). Chercheur principal. Anti-Clostridium difficile mechanisms of action of BioK+ probiotics - Étude des mécanismes d’action anti-Clostridium difficile par le probiotique Bio-K+. (2014-2015).

Subvention. (Terminé). Chercheur principal. Development of specific antibodies targeting the toxins, cell surface proteins, and spores of C. difficile - Développement d’anticorps spécifiques dirigés contre des protéines de surface des bactéries et des spores de C. difficile et ses toxines. (2013-2014).

Subvention. (Terminé). Co-chercheur. Development of a new class of antibiotics targeting the guanine riboswitch to fight C. difficile infections - Développement d'une nouvelle classe d'antibiotiques ciblant le riborégulateur guanine pour le traitement des infections à C. difficile. (2012-2014).

Subvention. (Terminé). Co-chercheur. Genetic, transcriptional and functional study of c-di-GMP signaling in C. difficile. - Signalisation cellulaire par le c-diGMP chez Clostridium difficile : étude génétique, transcriptionnelle et fonctionnelle. (2010-2013).

Subvention. (Obtenu). Co-chercheur. Initial vancomycin taper for the prevention of recurrent Clostridium difficile infection. Instituts de Recherche en Santé du Canada (IRSC). Projet. 378676 $

Publications

Articles de revue

  • *Garneau JR, Abou Chakraa CN, Fortier LC, Labbé AC, Simor AE, Gold W, Muller M, McGeer A, Powis J, Katz K, Pépin J and L Valiquette. (2019). Clostridioidis difficileMultilocus Variable-Number Tandem-Repeat Analysisof Clustersin Ribotype 027 Isolates and Lack of Association with Clinical Outcomes. Journal of Clinical Microbiology, 26(57), e01724-18. (Article publié).
  • Fortier, LC. (2018). Clostridioides (Clostridium) difficileBacteriophages contribute to shaping species. Frontiers in Microbiology (commissioned article), 9, 2033. (Article publié).
  • Yan LH, Le Roux A, Boyapelly K, Lamontagne AM, Archambault MA, Picard-Jean F, Lalonde-Seguin D, St-Pierre E, Najmanovich RJ, Fortier LC, Lafontaine D, Marsault É. (2018). Clostridioides difficilePurine analogs targeting the guanine riboswitch as potential antibiotics against . European Journal of Medicinal Chemistry, 143, 755-757. (Article publié).
  • Carignan A, Fortier LC. (2018). Discovery of keyicin, a new antibiotic: it takes two to tango. Médecine/Sciences, 34(5), 377-379. (Article publié).
  • *Garneau J, *Sekulovic O, Dupuy B, Soutourina O, Monot M, Fortier LC. (2018). High Prevalence and Genetic Diversity of Large phiCD211 (phiCDIF1296T)-Like Prophages in Clostridioides difficile. Applied and Environmental Microbiology, 84(3), e02164-17. (Article publié).
  • Allard M*, Bergeron J*, Baharnoori M, Srivastava L, Fortier LC, Poyart C, Sébire G. (2017). A sexually dichotomous, autistic-like phenotype is induced by Group B Streptococcus maternofetal immune activation. Autism Research, 10(2), 233-245. (Article publié).
  • Tremblay S*,Côté NML*, Grenier G, Duclos-Lasnier G, Fortier LC, Ilangumaran S, Menendez A. (2017). Ileal antimicrobial peptide expression is dysregulated in old age. Immunity & Aging, 14(19), 1-5. (Article publié).
  • *Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data. Scientific Reports, 7, 1-10. (Article publié).
  • Bergeron J, Gerges N, Guiraut C, Djordje Grbic, Allard MJ, Fortier LC, Vaillancourt C, Sébire G. (2016). Activation of the IL-1?/CXCL1/MMP-10 axis in chorioamnionitis induced by inactivated Group B Streptococcus. Placenta, 47, 116-123. (Article publié).
  • Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold WL, Muller MP, Powis J, Katz K, *Garneau JR, Fortier LC, Pépin J, Cadarette SM, Valiquette L. (2015). Clostridium difficileFactors Associated With Complications of Infection in a Multicenter Prospective Cohort. Clinical Infectious Diseases, 61(12), 1781-1788. (Article publié).
  • Boudry P, Semenova E, Monot M, Datsenko KA, Lopatina A, *Sekulovic O, *Ospina-Bedoya M, Fortier LC, Severinov K, Dupuy B, Soutourina O. (2015). Clostridium difficileFunction of the CRISPR-Cas System of the Human Pathogen . mBio, 6(5), e01112-15. (Article publié).
  • *Sekulovic O, *Ospina Bedoya M, Fivian-Hughes AS, Fariweather NF, Fortier LC. (2015). Clostridium difficileThe Cell Wall Protein CwpV Confers Phase-Variable Phage Resistance. Molecular Microbiology, 98(2), 329-342. (Article publié).
  • Bordeleau E, Purcell EB, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2015). Cyclic-di-GMP riboswitch-regulated type IV pili contribute to aggregation of Clostridium difficile. Journal of Bacteriology, 197(5), 819-832. (Article publié).
  • Bergeron J, Deslauriers J, Grignon S, Fortier LC, Lepage M, Stroh T, Poyart C, Sébire G. (2015). Exposition to group B streptococcal maternalinflammation: White matter injury and autistic-like behavior predominantlyaffecting male rat offspring. Int J Dev Neurosci, 47(A), 47-48. (Article publié).
  • *Sekulovic O, Fortier LC. (2015). Global transcriptional response of Clostridium difficile carrying the ?CD38-2 prophage. Applied and Environmental Microbiology, 81(4), 1364-1374. (Article publié).
  • Allard MJ, Bergeron J, Grbic D, Fortier LC, Poyart C, Sébire G. (2015). StreptococcusGroup B infection during gestation induces gender specific neurodevelopmentalimpairments. Int J Dev Neurosci, 61(12), 86. (Article publié).
  • *Sekulovic O, *Garneau JR, *Néron A, Fortier LC. (2014). Characterization of Temperate Phages Infecting Clostridium difficile Isolates from Human and Animal Origin. Applied and environmental microbiology, 80(8), 2555-2563. (Article publié).
  • *Garneau JR, Valiquette L, Fortier LC. (2014). Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC infectious diseases, 14(1), 29. (Article publié).
  • Fortier LC, *Sekulovic O. (2013). Importance of prophages to evolution and virulence of bacterial pathogens. Virulence, 4(5), 354-365. (Article publié).
  • Bergeron JD , Deslauriers J , Grignon S , Fortier LC , Lepage M , Stroh T , Poyart C , Sébire G. (2013). White matter injury and autistic-like behavior predominantly affecting male rat offspring exposed to group B streptococcal maternal inflammation. Developmental neuroscience, 35(6), 504-515. (Article publié).
  • *Meessen-Pinard M , *Sekulovic O , Fortier LC. (2012). Evidence of in vivo prophage induction during Clostridium difficile infection. Applied and environmental microbiology, 78(21), 7662-7670. (Article publié).
  • Gebhart D , Williams SR , Bishop-Lilly KA , Govoni GR , Willner KM , Butani A , Sozhamannan S , Martin D , Fortier LC , Scholl D. (2012). Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile. Journal of bacteriology, 194(22), 6240-6247. (Article publié).
  • *Sirard S , Valiquette L , Fortier LC. (2011). Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. Journal of clinical microbiology, 49(12), 4040-4046. (Article publié).
  • *Sekulovic O , *Meessen-Pinard M , Fortier LC. (2011). Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. Journal of bacteriology, 193(11), 2726-2734. (Article publié).
  • Bordeleau E , Fortier LC , Malouin F , Burrus V. (2011). c-di-GMP turn-over in Clostridium difficile is controlled by a plethora of diguanylate cyclases and phosphodiesterases. PLoS genetics, 7(3), e1002039. (Article publié).
  • Gonzales M , Pepin J , Frost EH , Carrier JC , Sirard S , Fortier LC , Valiquette L. (2010). Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC infectious diseases, 10, (Article publié).
  • Mulhbacher J , Brouillette E , Allard M , Fortier LC , Malouin F , Lafontaine DA. (2010). Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. PLoS pathogens, 6(4), e1000865. (Article publié).
  • Matte I , Lane D , Côté E , Asselin AE , Fortier LC , Asselin C , Piché A. (2009). Antiapoptotic proteins Bcl-2 and Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells. Infection and immunity, 77(12), (Article publié).
  • Haaber J , Moineau S , Fortier LC , Hammer K. (2008). AbiV, a novel antiphage abortive infection mechanism on the chromosome of Lactococcus lactis subsp. cremoris MG1363. Applied and environmental microbiology, 74(21), (Article publié).
  • Fortier LC , Moineau S. (2007). Morphological and genetic diversity of temperate phages in Clostridium difficile. Applied and environmental microbiology, 73(22), (Article publié).
  • Fortier LC , Bransi A , Moineau S. (2006). Genome sequence and global gene expression of Q54, a new phage species linking the 936 and c2 phage species of Lactococcus lactis. Journal of bacteriology, 188(17), (Article publié).
  • Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. (2006). The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug metabolism and disposition: the biological fate of chemicals, 34(7), (Article publié).
  • Fortier LC , Bouchard JD , Moineau S. (2005). Expression and site-directed mutagenesis of the lactococcal abortive phage infection protein AbiK. Journal of bacteriology, 187(11), (Article publié).
  • Girard H , Thibaudeau J , Court MH , Fortier LC , Villeneuve L , Caron P , Hao Q , von Moltke LL , Greenblatt DJ , Guillemette C. (2005). UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology (Baltimore, Md.), 42(2), (Article publié).
  • Girard H , Court MH , Bernard O , Fortier LC , Villeneuve L , Hao Q , Greenblatt DJ , von Moltke LL , Perussed L , Guillemette C. (2004). Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics, 14(8), (Article publié).
  • Fortier LC , Tourdot-Maréchal R , Diviès C , Lee BH , Guzzo J. (2003). Induction of Oenococcus oeni H+-ATPase activity and mRNA transcription under acidic conditions. FEMS microbiology letters, 222(2), (Article publié).
  • Villeneuve L , Girard H , Fortier LC , Gagné JF , Guillemette C. (2003). Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. The Journal of pharmacology and experimental therapeutics, 307(1), (Article publié).
  • Guzzo J , Jobin MP , Delmas F , Fortier LC , Garmyn D , Tourdot-Maréchal R , Lee B , Diviès C. (2000). Regulation of stress response in Oenococcus oeni as a function of environmental changes and growth phase. International journal of food microbiology, 55(1-3), (Article publié).
  • Tourdot-Maréchal R , Fortier LC , Guzzo J , Lee B , Diviès C. (1999). Acid sensitivity of neomycin-resistant mutants of Oenococcus oeni: a relationship between reduction of ATPase activity and lack of malolactic activity. FEMS microbiology letters, 178(2), (Article publié).
  • Fortier LC , Delbecchi L , Bourgaux-Ramoisy D , Bourgaux P. (1998). Rescue of polyomavirus DNA after co-transfection of recombinant plasmids with viral DNA fragments. Biochimica et biophysica acta, 1395(1), (Article publié).

Chapitres de livre

  • Fortier, LC. (2017). The contribution of bacteriophages to the biology and virulence of pathogenic clostridia. Gadd GM, Sariaslani S Advances in Applied Microbiology (101, 1-10). Pays-Bas : Elsevier. (Article publié).
  • Sekulovic O, Fortier LC. (2016). Characterization of functional prophages in Clostridium difficile. Adam Roberts and Peter Mullany Methods in Molecular Biology - Clostridium difficile. Invited chapter (476, 143-65). Royaume-Uni : Humana Press. (Article publié).
  • Fortier LC, Moineau S. (2009). Phage production and maintenance of stocks, including expected stock lifetimes. Clokie MRJ and Kropinski AM Methods in Molecular biology (501, 203-219). États-Unis : Clokie MRJ and AM Kropinski. (Article publié).

Articles de conférence

  • Bouchard ME, Fortier LC, Rousseau E, Girard I. (2019). ***This poster won the first prize***Pathophysiologie des ulcérations chez les patientes porteuses de pessaire. Annual meeting of the association of gynecologists and obstetricians of Quebec (AOGQ). (Article publié).
  • Garneau JR, Peltier J, Hamiot A, Tremblay Y, Turcotte A, Dupuy B, Valiquette L, Monot M, Fortier LC. (2019). Clostridioides difficileImpacts of the phi027 prophage on the biology and virulence of the epidemic strain ribotype 027. Annual meeting of the Canadian Society of Microbiologists (CSM). (Article publié).
  • Jann J, Drevelle O, Dumont M, Bernier JL, Agbe H, Sarkar DK, Chen XG, Soucy G, Fortier LC, and Faucheux N. (2019). Development of biocidal surface technology based on anodized aluminum designed to fight nosocomial infections. 69th Canadian Chemical Engineering Conference. (Article accepté).
  • Bouchard ME, Fortier LC, Rousseau E, Girard I. (2019). Pathophysiology of ulcerations in women using pessary; experimental study. International Urogynecological Association (IUGA)/American Urogynecologic Society (AUGS) joint annual meeting. (Article accepté).
  • Fortier LC. (2018). C. difficile phages. 6th International Clostridium dificile Symposium (ICDS). (Article soumis).
  • Allen MM, Ospina-Bedoya M, Kirk J, Fagan R, Govoni G, Fortier LC. (2018). Clostridium difficileThe surface layer proteinA (SlpA) serves as a general receptor for bacteriophage infection. 68th annual conference of the Canadian Society of Microbiologists (CSM). (Article soumis).
  • Pasquier JC, Lewin A, St-Pierre E, Gillet V, Fortier LC. (2017). Fecal transplants disturb length of pregnancy in a mouse model. 37th Annual pregnancy meeting of the Society of Maternal-Fetal Medicine (SMFM) (Jan 23-28). Las Vegas, NV, USA. (Article publié).
  • Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). PhageTerm: a Fast and User-friendly Software to Determine Bacteriophage Termini and Packaging Mode using randomly fragmented NGS data. Centennial Celebration of Bacteriophage Research (April 24-26). Institut Pasteur, Paris, France. (Article accepté).
  • Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). Phageterm: a fast and user-friendly software todetermine bacteriophage termini and packaging mode using randomly fragmented NGSdata. Annual meeting of the Canadian Society for Microbiologists (CSM) (June 20-23) Waterloo, ON, Canada. (Article accepté).
  • Allard MJ, Guiraut C, Descoteaux M, Tremblay L, Lepage M, Fortier LC, Sébire G. (2017). StreptococcusPlacental group B infection: sex specific inflammatory response andautistic-like traits in male offspring. Meeting of the International Society for Autism Research (INSAR/IMFAR) (May 10-13). San Francisco, CA, USA. (Article accepté).
  • Larocque M, Fortier LC, Najmanovich R. (2016). Clostridium difficileIntegrative approach in drugs discovery pipeline applied to . ISMB/SigBio joint meetings, Orlando, FL, USA July 8-12. (Article publié).
  • Garneau JR, Monot M, Valiquette L, Fortier LC. (2016). Clostridium difficileProphage elements as a significant source of genetic diversity among epidemic R027 clinical isolates of . Annual meeting of the Canadian Society for Microbiologists (CSM). (Article publié).
  • Ospina-Bedoya M, Fagan R, Govoni G, Fortier LC. (2016). Clostridium difficileRole of the Surface Layer Protein A in bacteriophage infection. Annual meeting of the Canadian Society for Microbiologists (CSM). (Article publié).
  • Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold W, Muller MP, Devlin R, Powis J, Katz K, Garneau JR, Fortier LC, Pépin J, Valiquette L. (2015). Clostridium difficileIndependent Risk Factors for Recurrence of Infection: ACanadian Multicenter Prospective Cohort. IDWeek. (Article publié).
  • Garneau JR, Abou Chakra CN, Labbé AC, McGeer A, Pépin J, Valiquette L, Fortier LC. (2015). ClostridiumdifficileRelationship between MLVA genetic types andclinical outcomes following infection by ribotype 027. 5th ICDS meeting. (Article publié).
  • Michaud A, Smith-Peter E, Lafontaine DA, Fortier LC. (2015). Clostridium difficileThe riboswitch-controlled GMP synthase GuaA is important for survival andvirulence of and in a mouse model ofinfection. Annual meeting of the RiboClub. (Article publié).
  • Sekulovic O, Fortier LC. (2014). Clostridium difficileA first glance atphage-host interactions in . General meeting of the American Society for Microbiology (ASM. (Article publié).
  • Garneau JR, Abou Chakra CN, Fortier LC, Labbé AC, McGeer A, Pépin J, Valiquette L. (2014). Clostridium difficileAnalyse de l'impact des types génétiques bactériens MLVA sur les issues cliniques d'infection par ribotype 027. Annual meeting of the Association des Médecins Microbiologistes infectiologues du Québec - AMMIQ. (Article publié).
  • Bordeleau E, Purcell EB, Paquette-D’Avignon M, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2014). Cyclic-di-GMP signaling and type IV pili-mediated aggregation in Clostridium difficile. 114th General meeting of the America Society for Microbiology (ASM). (Article publié).
  • Allard MJ, Bergeron J, Grbic D, Fortier LC, Poyart C, Sébire G. (2014). StreptococcusGroup B infection during gestation induces gender specific neurodevelopmentalimpairments. Joint Meeting of the 20th Biennial Meeting of the International Society for Developmental Neuroscience and the 5th Annual NeuroDevNet Brain Development Conference (ISDN, NeuroDevNet 2014). (Article publié).
  • Allard MJ, Bergeron J, Fortier LC, Poyart C, Sébire G. (2014). StreptococcusGroup B infection during gestation leads to gender specific neurodevelopmental andbehavioural impairments. Annual Meeting of the Society for Neuroscience. (Article publié).
  • Garneau JR, Sekulovic O, Néron A, Fortier LC. (2014). Temperate phages of Clostridium difficile isolated from farm animals. 114th General meeting of the America Society for Microbiology (ASM). (Article publié).
  • Sekulovic O, Fortier LC. (2013). A First Glance at Phage-Host Interactions in Clostridium difficile. 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. (Article publié).
  • Bergeron J, Brochu ME, Deslauriers J, Grignon S, Fortier LC, Sébire G. (2013). Gestational exposure to inactivated Group B Streptococcus induced gender-dependent brain damage and autistic features in offspring. Pediatric Academic Societies/Eastern Society for Pediatric Research Annual Meeting. (Article publié).
  • Bergeron J, Allard MJ, Deslauriers J, Grignon S, Sarret P, Fortier LC, Poyart C, Sébire G. (2013). Group B Streptococcus inflammatory response induced during gestation recapitulates perinatal injuries and subsequent behavioral impairments affecting premature human newborn such as autistic features in male offspring. Meeting of the Society for Neuroscience. (Article publié).
  • Abou Chakra CN, Labbé AC, McGeer A, Simor A, Gold W, Devlin R, Katz K, Powis J, Fortier LC, Muller MP, Garneau JR, Pepin J, Valiquette L. (2013). Risk factors for complications of Clostridium difficile Infection in a prospective multicentre cohort. IDWeek. (Article publié).
  • Gebhart D, Scholl D, Vacin C, Fortier LC, Williams S, Govoni G. (2012). Diffocins: novel, high-molecular weight bacteriocins highly specific for Clostridium difficile. 4th International Conference on Clostridium difficile (4th ICDS). (Article publié).
  • St-Pierre E, Lalonde Séguin D, Burrus V, Fortier LC. (2012). Inactivation of chemotaxis-associated genes increases flagellar motility in Clostridium difficile. 4th International Conference on Clostridium difficile (4th ICDS). (Article publié).
  • Garneau JR, Valiquette L, Fortier LC. (2012). La sporulation de Clostridium difficile est inhibée par des concentrations sous-inhibitrices de tigecycline et de piperacillin-tazobactam in vitro. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • St-Pierre E, Pépin ME, Burrus V, Fortier LC. (2012). Rôle de la mobilité et du chimiotactisme dans la virulence de Clostridium difficile. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Kelly M, Fortier LC. (2011). Antimicrobial activity of beta-bio 45% hops extract against Clostridium difficile NAP1/027 (Abstract #32532). 49th Annual Meeting of the Infectious Diseases Society of America - IDSA. (Article publié).
  • Sirard S, Valiquette L, Fortier LC. (2011). Can the clinical outcomes associated with Clostridium difficile Infections (CDI) be predicted by bacterial genotype and phenotypes?. Annual meeting of the Association des Médecins Microbiologistes infectiologues - AMMI. (Article publié).
  • Bergeron J, Girard S, Brochu ME, Fortier LC, Sébire G. (2011). Implication du Streptocoque de groupe B dans les lésions cérébrales périnatales. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Gebhart D, Williams S, Fortier LC, Govoni G, Scholl D. (2011). Phage tail-like bacteriocins of Clostridium difficile. 7th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (ClosPath). (Article publié).
  • Bergeron J, Girard S, Brochu ME, Fortier LC, Sebire G. (2011). Role of gestational inflammation induced by group B streptococcus in perinatal brain lesions and subsequent cerebral palsy. 40th Annual Meeting of the Child Neurology Society. (Article publié).
  • Néron A, Sekulovic O, Fortier LC. (2010). Diversité et biologie des bacteriophages de Clostridium difficile isolés de souches animales. Annual Pharmacology meeting, faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Pinard MM, Fortier LC. (2010). In vivo prophage induction in patients infected by Clostridium difficile. Viruses of Microbes meeting. (Article publié).
  • Bergeron J, Girard S, Brochu ME, Fortier LC, Sébire G. (2010). Mise au point d’un modèle animal de paralysie cérébrale par exposition gestationnelle au Streptocoque de groupe B inactivé. Annual meeting of Pediatrics, Sherbrooke hospital center (CHUS). (Article publié).
  • Sirard S, Valiquette L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur le phénotype et le génotype bactériens ?. 39th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Sirard, S, Valiquette, L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur l’analyse génotypique et phénotypique des souches bactériennes?. 78th Meeting of the ACFAS. (Article publié).
  • Sekulovic O, Fortier LC. (2010). Prophage-enhanced toxin production in Clostridium difficile NAP1/027 lysogens. Viruses of Microbes meeting. (Article publié).
  • Sirard S, Valiquette L, Fortier LC. (2010). Prédire la sévérité des infections à C. difficile : plus difficile qu’il n’y paraît !. Annual research meeting of the Université de Sherbrooke. (Article publié).
  • Fortier LC, Matte I, Côté É, Asselin A-É, Asselin C, Piché A. (2009). Anti-apoptotic proteins Bcl-2/Bcl-XL protect from Clostridium difficile toxin A-induced cell death. 26th International Congress of Chemotherapy and Infection (ICC). (Article publié).
  • Sekulovic O, Fortier LC. (2009). Impact des prophages sur la biologie de Clostridium difficile. 38th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Pinard MM, Fortier LC. (2009). La phagothérapie contre Clostridium difficile : une réalité ?. 38th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Mauler S, Pinard MM, Sekulovic O, Fortier LC. (2009). Les bactériophages contre C. difficile : réalité ou utopie ?. Annual research meeting of the Université de Sherbrooke. (Article publié).
  • Haaber J, Moineau S, Fortier LC, Hammer K. (2008). AbiV, a novel abortive phage infection mechanism on the chromosome of Lactococcus lactis subsp. cremoris MG1363. 9th Symposium on Lactic Acid Bacteria. (Article publié).
  • Pinard MM, Sekulovic O, Fortier LC. (2008). Les phages de Clostridium difficile : rôle dans la virulence et potentiel thérapeutique. 37th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Pinard MM, Sekulovic O, Fortier LC. (2008). Les phages de Clostridium difficile : rôle dans la virulence et potentiel thérapeutique. Annual research meeting of the Université de Sherbrooke. (Article publié).
  • Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. 37th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
  • Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. Annual research meeting of the Université de Sherbrooke. (Article publié).

Propriétés intellectuelles

Brevets

  • GAUDREAU S, CLOUTIER M, FORTIER LC, LEDUC F, Tremblay M, VERONNEAU S, GBRIC D, LARRIVEE JF. (2016). C. difficile antibodies directed thereto, and target for the treatment of humans and other animals intoxicated with at least one bacterial toxin A and/or B. 62118450. Canada. (Délivré).

Autres contributions

Cours enseignés

  • Antimicrobiens et chimiothérapie. PHR305. (2017-09-01). Université de Sherbrooke. Canada.
  • Microbiologie en pharmacologie. MCB103. (2016-09-01). Université de Sherbrooke. Canada.
  • Le microbiome dans la physiologie, l'immunologie et le métabolisme de l'hôte. MCR717. (2016-01-01). Université de Sherbrooke. Canada.

Activités de collaboration internationale

  • Principal investigator and Collaborator. (2012-2025). France. My team has been collaborating for several years with two groups in France, one at the Institut Pasteur in Paris (Marc Monot, David Bikard and Bruno Dupuy), and the other one in Université Paris-Sud (Olga Soutourina). My collaboration involves phage work related to CRISPRs, toxin/antitoxin systems, and phage-host interactions in C. difficile.
  • Collaborator. (2015-2023). Royaume-Uni. Clostridioides difficileI am collaborating with Robert P. Fagan from the University of Sheffield. He is an expert in the structure of the cell surface and cell wall composition of . He studies, among others, the interaction between phage tail-like particles, whole phage particles, and host receptors at the surface of . I collaborate with his group to pursue the characterisation of the detailed interaction between phages and C. difficile. Our work involves using various C. difficile mutants and plasmid constructions that R. Fagan developed, and I perform all the phage work.
  • Principal investigator. (2013-2015). Royaume-Uni. We started to collaborate with the group of Neil Fairweather on the study of the cell wall associated protein CwpV in C. difficile. They shared with us various constructions of CwpV and antibodies and we shared our recent research results with them. They are co-authors of a publication with us (Sekulovic et al, Mol. Microbiol. 2015, in press). Our objective is to work together to try to clarify the biological function of CwpV.

Présentations

  • Garneau JR, Peltier J, Hamiot A, Tremblay Y, Turcotte A, Dupuy B, Valiquette L, Monot M, Fortier LC. (2019). Impacts du prophage phi027 dans la biologie et la virulence de la souche épidémique Clostridioides difficile ribotype R027. Annual scientific retreat of the Inflammation & Pain research axis of the CHUS reserach center. Sherbrooke, Canada.
  • (2019). Phage-host interactions in Clostridioides difficile. Invited speaker for seminar series at Texas A&M, Department of Biology. Texas, États-Unis.
  • (2019). Phage-host interactions in the human pathogen Clostridium difficile. Phage Fest - 10th anniversary William & Mary University, Department of Biology, Integrated Science Center. Williamsburg, États-Unis.
  • (2018). C. difficile phages. 6th International Clostridium difficile symposium (ICDS). Bled, Slovénie.
  • (2018). Clostridium difficile et ses bactériophages. Invited speaker at Université Laval. Québec, Canada.
  • (2017). Interactions phages-hôte chez Clostridium difficile. Université Laval - Conférence invitée. Québec, Canada.
  • (2016). Interactions phages-hôte chez la bactérie pathogène Clostridium difficile. Conferences of the department of Immunology of the faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada.
  • (2016). La prescription des phages. French conference in medicine of Moncton. Moncton, Canada.
  • (2015). Le développement d'un nouvel antibiotique: de l'idée à la clinique. CursUS-Santé. Sherbrooke, Canada.
  • (2015). Phage-host interactions in Clostridium difficile. Invited speaker at the Institut Pasteur in Paris, France. Paris, France.
  • Sekulovic O, Ospina Bedoya M, Fairweather N, Fortier LC. (2015). The phase-variable cell wall protein CwpV confers phage resistance to Clostridium difficile. *This abstract was selected for an oral presentation by the review committee. 5th ICDS meeting. Bled, Slovénie.
  • Déziel E, Weiss K, Behr M, Fortier LC. (2014). "Les superbactéries, doit-on s'en préoccuper?" Superbugs, should we be preoccupied? I was invited as a microbiology expert (along with 3 other microbiologists) to discuss this topic with the public. Les grands rendez-vous scientifiques du Musée de l'Institut Armand-Frapier. Laval, Canada.
  • Sekulovic O, Fortier LC. (2014). A first glance at phage-host interactions in Clostridium difficile. * This abstract was selected for an oral presentation by the review committee, and won the Gisela Mosig prize for best abstract. General meeting of the American Society for Microbiology (ASM). Boston, États-Unis.
  • (2014). Développement d'une plateforme pour l'étude du microbiote intestinal. Technological conferences of the research axis in inflammation and pain of the CHUS research center. Sherbrooke, Canada.
  • (2014). Impact des antibiotiques sur la susceptibilité aux infections à Clostridium difficile: une approche intégrative. 56e réunion annuelle du Club de Recherche Clinique du Québec. Mont Gabriel, Canada.
  • Daniel Lafontaine Éric Marsault François Malouin. (2014). The guanine riboswitch as a target for the treatment of C. difficile and S. aureus infections. Second presentation in front of potential investors (Amorchem, Neomed and MSBiV). Montréal, Canada.
  • Bordeleau E, Purcell E, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2013). Cyclic-di-GMP riboswitch-controlled type IV pili-mediated aggregation in Clostridium difficile. 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. Palm Cove, Australie.
  • Fortier LC. (2013). Impact des antibiotiques sur la susceptibilité aux infections à Clostridium difficile: une approche integrative. First annual meeting of the Research Center on Inflammation and Cancer of the Université de Sherbrooke (CRICUS). Sherbrooke, Canada.
  • Fortier LC. (2013). Pathogenèse des infections à Clostridium difficile et développement de nouveaux antibiotiques. Annual research forum of the faculty of medicine of the Université de Sherbrooke. Magog, Canada.
  • Fortier LC. (2013). Phage-host interactions in the human pathogen Clostridium difficile. Seminars series at Memorial University. St-John's, Canada.
  • Daniel Lafontaine Éric Marsault François Malouin. (2013). The guanine riboswitch as a target for the treatment of C. difficile and S. aureus infections. First presentation in front of potential investors (Amorchem, Neomed and MSBiV). Montréal, Canada.
  • Fortier LC. (2012). Genetic diversity of Clostridium difficile and novel therapeutic strategies. Invited speaker at ViroPharma Inc. Exton, États-Unis.
  • Fortier LC. (2012). Pathogenesis of Clostridium difficile infections and novel therapeutic strategies. Invited speaker at AvidBiotics Inc. South San Francisco, États-Unis.
  • Fortier LC. (2012). Pathogénèse des infections à Clostridium difficile. Conférences en microbiologie et en biotechnologie. Sherbrooke, Canada.
  • (2011). Pathogenesis of Clostridium difficile infections and development of novel antimicrobial agents. Invited speaker for the annual CIHR Infection and Immunity consulting committee. Sherbrooke, Canada.
  • Garneau JR, Valiquette L, Fortier LC. (2011). Sub-inhibitory concentrations of tigecycline inhibit sporulation of Clostridium difficile in vitro. 7th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. Aymes, États-Unis.
  • Sirard S, Valiquette L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur l’analyse génotypique et phénotypique des souches bactériennes?. Annual Meeting of the Association des Médecins Microbiologistes Infectiologues du Québec (AMMIQ-JAFA). Québec, Canada.
  • Fortier LC, Sekulovic O, Meessen-Pinard M. (2010). The multiple facets of bacteriophages and their role in the diversity and virulence of C. difficile. 3rd International Clostridium difficile symposium. Bled, Slovénie.
  • Mulhbacher J, Brouillette E, Malouin F, Fortier LC, Lafontaine DA. (2009). Guanine riboswitch as a target for new antibiotics family. Invited seminar at the faculty of medicine of the U. of Montreal. Montreal, Canada.
  • Sekulovic O, Fortier LC. (2009). Impact des prophages sur la biologie de Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada.
  • Sirard S, Valiquette L, Fortier LC. (2009). Infections à C. difficile: quand C. difficile, ce n’est jamais simple!. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada.
  • Mulhbacher J, Fortier LC, Malouin F, Lafontaine DA. (2009). Novel antibioswitches as selective inhibitors of guanine-related metabolic pathways. 10th annual Eastern Ribo-club Opening Session. Magog, Canada.
  • Sekulovic O, Meessen-Pinard M, Fortier LC. (2009). Prophage-enhanced toxin production in Clostridium difficile NAP1/027 lysogens. "This abstract was selected for a slide presentation by the review committee". 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, États-Unis.
  • Mulhbacher J, Fortier LC, Malouin F, Lafontaine DA. (2009). Riboswitch guanine: nouvelle cible pour les antibioswitches. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada.
  • (2009). Rôle des bactériophages dans l’évolution et la virulence de Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel. Sherbrooke, Canada.
  • Mulhbacher J, Heppell B, Moisan H, Malouin F, Fortier LC, Lafontaine DA. (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. 10th annual Ontario-Québec Biotechnology meeting. Sherbrooke, Canada.
  • Mulhbacher J, Heppell B, Moisan H, Malouin F, Fortier LC, Lafontaine DA. (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. Conferences of the Ribo-club. Magog, Canada.
  • Mulhbacher J, Heppell B, Moisan H, Malouin F, Fortier LC, Lafontaine DA. (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. RNA meeting. Berlin, Allemagne.
  • Fortier LC. (2008). Potential of phage therapy to fight Clostridium difficile infections. Eliava-2008: Phage biology, ecology and therapy meeting. Tbilisi, Géorgie.
  • Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-Le Bel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.